Tags

Type your tag names separated by a space and hit enter

Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Adv Ther. 2009 Jun; 26(6):660-6.AT

Abstract

INTRODUCTION

In this study, we examined the effects of the alpha-glucosidase inhibitors acarbose and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus.

METHODS

Twenty-one Japanese patients with type 2 diabetes were enrolled in this study. Subjects had been treated with voglibose for at least 3 months. They underwent a 400 kcal balanced food meal tolerance test before and 8 weeks after the changeover from voglibose to acarbose. Subjects were divided into two groups: the first group (low-dose group; n=11) was changed over from 0.6 mg/day voglibose to 150 mg/day acarbose, and the other (high-dose group; n=10) from 0.9 mg/day voglibose to 300 mg/day acarbose.

RESULTS

The increment rate of postprandial plasma glucose ([plasma glucose 2 hours after test meal - fasting glucose]/fasting glucose) decreased from 34.7%+/-23.9% to 25.0%+/-24.6% (P=0.13) in the low-dose group, and decreased significantly from 56.1%+/-53.1% to 31.5%+/-36.0% (P=0.03) in the high-dose group after changeover. However, there were no significant changes in blood glycated hemoglobin (HbA(1c)) levels before and after changeover in either group. The increment rate of postprandial serum triglyceride (TG) ([serum TG 2 hours after test meal - fasting TG]/fasting TG) decreased significantly only in the high-dose group (52.4%+/-60.0% to 24.3%+/-16.6%) (P=0.05). No significant changes in serum high-density lipoprotein cholesterol levels were observed in either group, whereas serum low-density lipoprotein cholesterol levels decreased significantly from 3.20+/-0.25 to 2.65+/-0.18 mmol/L (P=0.04), only in the high-dose group.

CONCLUSIONS

In patients with type 2 diabetes our findings suggest that acarbose 300 mg/day is superior to voglibose 0.9 mg/day in improving postprandial hyperglycemia and hypertriglyceridemia.

Authors+Show Affiliations

Department of Endocrinology and Metabolism, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi 321-0293, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

19568704

Citation

Matsumura, Mihoko, et al. "Effects of Changeover From Voglibose to Acarbose On Postprandial Triglycerides in Type 2 Diabetes Mellitus Patients." Advances in Therapy, vol. 26, no. 6, 2009, pp. 660-6.
Matsumura M, Monden T, Miyashita Y, et al. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009;26(6):660-6.
Matsumura, M., Monden, T., Miyashita, Y., Kawagoe, Y., Shimizu, H., Nakatani, Y., Domeki, N., Yanagi, K., Ikeda, S., & Kasai, K. (2009). Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Advances in Therapy, 26(6), 660-6. https://doi.org/10.1007/s12325-009-0040-7
Matsumura M, et al. Effects of Changeover From Voglibose to Acarbose On Postprandial Triglycerides in Type 2 Diabetes Mellitus Patients. Adv Ther. 2009;26(6):660-6. PubMed PMID: 19568704.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. AU - Matsumura,Mihoko, AU - Monden,Tsuyoshi, AU - Miyashita,Yasushi, AU - Kawagoe,Yoshiaki, AU - Shimizu,Hiroaki, AU - Nakatani,Yuki, AU - Domeki,Nozomi, AU - Yanagi,Kazunori, AU - Ikeda,Shiori, AU - Kasai,Kikuo, Y1 - 2009/06/30/ PY - 2009/04/07/received PY - 2009/7/2/entrez PY - 2009/7/2/pubmed PY - 2009/12/16/medline SP - 660 EP - 6 JF - Advances in therapy JO - Adv Ther VL - 26 IS - 6 N2 - INTRODUCTION: In this study, we examined the effects of the alpha-glucosidase inhibitors acarbose and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus. METHODS: Twenty-one Japanese patients with type 2 diabetes were enrolled in this study. Subjects had been treated with voglibose for at least 3 months. They underwent a 400 kcal balanced food meal tolerance test before and 8 weeks after the changeover from voglibose to acarbose. Subjects were divided into two groups: the first group (low-dose group; n=11) was changed over from 0.6 mg/day voglibose to 150 mg/day acarbose, and the other (high-dose group; n=10) from 0.9 mg/day voglibose to 300 mg/day acarbose. RESULTS: The increment rate of postprandial plasma glucose ([plasma glucose 2 hours after test meal - fasting glucose]/fasting glucose) decreased from 34.7%+/-23.9% to 25.0%+/-24.6% (P=0.13) in the low-dose group, and decreased significantly from 56.1%+/-53.1% to 31.5%+/-36.0% (P=0.03) in the high-dose group after changeover. However, there were no significant changes in blood glycated hemoglobin (HbA(1c)) levels before and after changeover in either group. The increment rate of postprandial serum triglyceride (TG) ([serum TG 2 hours after test meal - fasting TG]/fasting TG) decreased significantly only in the high-dose group (52.4%+/-60.0% to 24.3%+/-16.6%) (P=0.05). No significant changes in serum high-density lipoprotein cholesterol levels were observed in either group, whereas serum low-density lipoprotein cholesterol levels decreased significantly from 3.20+/-0.25 to 2.65+/-0.18 mmol/L (P=0.04), only in the high-dose group. CONCLUSIONS: In patients with type 2 diabetes our findings suggest that acarbose 300 mg/day is superior to voglibose 0.9 mg/day in improving postprandial hyperglycemia and hypertriglyceridemia. SN - 0741-238X UR - https://www.unboundmedicine.com/medline/citation/19568704/Effects_of_changeover_from_voglibose_to_acarbose_on_postprandial_triglycerides_in_type_2_diabetes_mellitus_patients_ L2 - https://dx.doi.org/10.1007/s12325-009-0040-7 DB - PRIME DP - Unbound Medicine ER -